OBJECTIVE: Cross-sectional studies of optical coherence tomography (OCT) show that retinal nerve fiber layer (RNFL) thickness is reduced in multiple sclerosis (MS) and correlates with visual function. We determined how longitudinal changes in RNFL thickness relate to visual loss. We also examined patterns of RNFL thinning over time in MS eyes with and without a prior history of acute optic neuritis (ON). METHODS: Patients underwent OCT measurement of RNFL thickness at baseline and at 6-month intervals during a mean follow-up of 18 months at 3 centers. Low-contrast letter acuity (2.5%, 1.25% contrast) and visual acuity (VA) were assessed. RESULTS: Among 299 patients (593 eyes) with >or=6 months follow-up, eyes with visual loss showed greater RNFL thinning compared to eyes with stable vision (low-contrast acuity, 2.5%: p < 0.001; VA: p = 0.005). RNFL thinning increased over time, with average losses of 2.9microm at 2 to 3 years and 6.1microm at 3 to 4.5 years (p < 0.001 vs 0.5-1-year follow-up interval). These patterns were observed for eyes with or without prior history of ON. Proportions of eyes with RNFL loss greater than test-retest variability (>or=6.6microm) increased from 11% at 0 to 1 year to 44% at 3 to 4.5 years (p < 0.001). INTERPRETATION: Progressive RNFL thinning occurs as a function of time in some patients with MS, even in the absence of ON, and is associated with clinically significant visual loss. These findings are consistent with subclinical axonal loss in the anterior visual pathway in MS, and support the use of OCT and low-contrast acuity as methods to evaluate the effectiveness of putative neuroprotection protocols.
OBJECTIVE: Cross-sectional studies of optical coherence tomography (OCT) show that retinal nerve fiber layer (RNFL) thickness is reduced in multiple sclerosis (MS) and correlates with visual function. We determined how longitudinal changes in RNFL thickness relate to visual loss. We also examined patterns of RNFL thinning over time in MS eyes with and without a prior history of acute optic neuritis (ON). METHODS:Patients underwent OCT measurement of RNFL thickness at baseline and at 6-month intervals during a mean follow-up of 18 months at 3 centers. Low-contrast letter acuity (2.5%, 1.25% contrast) and visual acuity (VA) were assessed. RESULTS: Among 299 patients (593 eyes) with >or=6 months follow-up, eyes with visual loss showed greater RNFL thinning compared to eyes with stable vision (low-contrast acuity, 2.5%: p < 0.001; VA: p = 0.005). RNFL thinning increased over time, with average losses of 2.9microm at 2 to 3 years and 6.1microm at 3 to 4.5 years (p < 0.001 vs 0.5-1-year follow-up interval). These patterns were observed for eyes with or without prior history of ON. Proportions of eyes with RNFL loss greater than test-retest variability (>or=6.6microm) increased from 11% at 0 to 1 year to 44% at 3 to 4.5 years (p < 0.001). INTERPRETATION: Progressive RNFL thinning occurs as a function of time in some patients with MS, even in the absence of ON, and is associated with clinically significant visual loss. These findings are consistent with subclinical axonal loss in the anterior visual pathway in MS, and support the use of OCT and low-contrast acuity as methods to evaluate the effectiveness of putative neuroprotection protocols.
Authors: Daniel A Rosser; Simon N Cousens; Ian E Murdoch; Fred W Fitzke; David A H Laidlaw Journal: Invest Ophthalmol Vis Sci Date: 2003-08 Impact factor: 4.799
Authors: R Rudick; J Antel; C Confavreux; G Cutter; G Ellison; J Fischer; F Lublin; A Miller; J Petkau; S Rao; S Reingold; K Syndulko; A Thompson; J Wallenberg; B Weinshenker; E Willoughby Journal: Ann Neurol Date: 1997-09 Impact factor: 10.422
Authors: L J Balcer; M L Baier; V S Pelak; R J Fox; S Shuwairi; S L Galetta; G R Cutter; M G Maguire Journal: Mult Scler Date: 2000-06 Impact factor: 6.312
Authors: E Fisher; R A Rudick; G Cutter; M Baier; D Miller; B Weinstock-Guttman; M K Mass; D S Dougherty; N A Simonian Journal: Mult Scler Date: 2000-12 Impact factor: 6.312
Authors: L J Balcer; M L Baier; J A Cohen; M F Kooijmans; A W Sandrock; M L Nano-Schiavi; D C Pfohl; M Mills; J Bowen; C Ford; F R Heidenreich; D A Jacobs; C E Markowitz; W H Stuart; G-S Ying; S L Galetta; M G Maguire; G R Cutter Journal: Neurology Date: 2003-11-25 Impact factor: 9.910
Authors: B Weinstock-Guttman; M Baier; R Stockton; A Weinstock; T Justinger; F Munschauer; C Brownscheidle; J Williams; E Fisher; D Miller; R Rudick Journal: Mult Scler Date: 2003-10 Impact factor: 6.312
Authors: Michaela A Seigo; Elias S Sotirchos; Scott Newsome; Aleksandra Babiarz; Christopher Eckstein; E'tona Ford; Jonathan D Oakley; Stephanie B Syc; Teresa C Frohman; John N Ratchford; Laura J Balcer; Elliot M Frohman; Peter A Calabresi; Shiv Saidha Journal: J Neurol Date: 2012-03-15 Impact factor: 4.849
Authors: Carlos E Mendoza-Santiesteban; Jose-Alberto Palma; Jose Martinez; Lucy Norcliffe-Kaufmann; Thomas R Hedges; Horacio Kaufmann Journal: Mov Disord Date: 2015-09-11 Impact factor: 10.338
Authors: Amy T Waldman; Girish Hiremath; Robert A Avery; Amy Conger; Stacy L Pineles; Michael J Loguidice; Lauren S Talman; Kristin M Galetta; Michael J Shumski; James Wilson; E'tona Ford; Amy M Lavery; Darrel Conger; Benjamin M Greenberg; Jonas H Ellenberg; Elliot M Frohman; Laura J Balcer; Peter A Calabresi Journal: Mult Scler Relat Disord Date: 2013-05-01 Impact factor: 4.339
Authors: Anna M Pietroboni; Tiziana Carandini; Laura Dell'Arti; Francesca Bovis; Annalisa Colombi; Milena A De Riz; Elena Casazza; Elisa Scola; Chiara Fenoglio; Andrea Arighi; Giorgio G Fumagalli; Fabio Triulzi; Daniela Galimberti; Francesco Viola; Elio Scarpini Journal: Neurol Sci Date: 2020-04-30 Impact factor: 3.307